This company listing is no longer active
De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!
Idogen Inkomsten in het verleden
Verleden criteriumcontroles 0/6
Idogen's earnings have been declining at an average annual rate of -11.4%, while the Biotechs industry saw earnings growing at 4.6% annually. Revenues have been growing at an average rate of 19.3% per year.
Belangrijke informatie
-11.4%
Groei van de winst
51.4%
Groei van de winst per aandeel
Biotechs Groei van de industrie | 0.7% |
Inkomstengroei | 19.3% |
Rendement op eigen vermogen | -2,166.6% |
Nettomarge | -5,713.0% |
Volgende winstupdate | 23 Aug 2023 |
Recente prestatie-updates uit het verleden
Recent updates
Opbrengsten en kosten
Hoe Idogen geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.
Inkomsten en omzetgeschiedenis
Datum | Inkomsten | Inkomsten | G+A Uitgaven | R&D-uitgaven |
---|---|---|---|---|
31 Mar 23 | 1 | -44 | 44 | 0 |
31 Dec 22 | 0 | -48 | 47 | 0 |
30 Sep 22 | 3 | -50 | 52 | 0 |
30 Jun 22 | 11 | -41 | 50 | 0 |
31 Mar 22 | 12 | -39 | 50 | 0 |
31 Dec 21 | 14 | -39 | 51 | 0 |
30 Sep 21 | 13 | -33 | 44 | 0 |
30 Jun 21 | 7 | -33 | 38 | 0 |
31 Mar 21 | 8 | -31 | 37 | 0 |
31 Dec 20 | 8 | -27 | 33 | 0 |
30 Sep 20 | 7 | -27 | 33 | 0 |
30 Jun 20 | 6 | -29 | 34 | 0 |
31 Mar 20 | 5 | -32 | 32 | 0 |
31 Dec 19 | 4 | -33 | 31 | 0 |
30 Sep 19 | 7 | -29 | 30 | 0 |
30 Jun 19 | 6 | -30 | 30 | 0 |
31 Mar 19 | 5 | -27 | 31 | 0 |
31 Dec 18 | 4 | -28 | 31 | 0 |
30 Sep 18 | 0 | -30 | 30 | 0 |
30 Jun 18 | 0 | -29 | 29 | 0 |
31 Mar 18 | 0 | -25 | 25 | 0 |
31 Dec 17 | 0 | -21 | 21 | 0 |
30 Sep 17 | 0 | -18 | 25 | 0 |
30 Jun 17 | 0 | -14 | 19 | 0 |
31 Mar 17 | 0 | -13 | 13 | 0 |
31 Dec 16 | 0 | -13 | 13 | 0 |
30 Sep 16 | 0 | -12 | 10 | 0 |
30 Jun 16 | 0 | -12 | 10 | 0 |
31 Mar 16 | 0 | -10 | 12 | 0 |
31 Dec 15 | 0 | -10 | 10 | 0 |
30 Sep 15 | 0 | -8 | 2 | 0 |
30 Jun 15 | 1 | -6 | 2 | 0 |
31 Mar 15 | 0 | -4 | 1 | 0 |
31 Dec 14 | 0 | -2 | 1 | 0 |
31 Dec 13 | 0 | 0 | 0 | 0 |
31 Dec 12 | 0 | 0 | 0 | 0 |
Kwaliteitswinsten: IDOGEN is currently unprofitable.
Groeiende winstmarge: IDOGEN is currently unprofitable.
Analyse vrije kasstroom versus winst
Analyse van de winstgroei in het verleden
Winsttrend: IDOGEN is unprofitable, and losses have increased over the past 5 years at a rate of 11.4% per year.
Versnelling van de groei: Unable to compare IDOGEN's earnings growth over the past year to its 5-year average as it is currently unprofitable
Winst versus industrie: IDOGEN is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-12%).
Rendement op eigen vermogen
Hoge ROE: IDOGEN has a negative Return on Equity (-2166.6%), as it is currently unprofitable.